ROCHE I/ CH0012032113 /
31/05/2024 17:30:41 | Chg. +2.60 | Volume | Bid18:11:38 | Ask18:11:38 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
252.80CHF | +1.04% | 159,334 Turnover: 40.26 mill. |
250.20Bid Size: 20 | 259.80Ask Size: 134 | 213.91 bill.CHF | 3.76% | 17.56 |
GlobeNewswire
14/05
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
GlobeNewswire
09/05
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire
03/04
UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Inju...
GlobeNewswire
02/04
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting C...
GlobeNewswire
22/03
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highl...
GlobeNewswire
14/03
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides C...
GlobeNewswire
26/02
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Ro...
GlobeNewswire
21/02
REPARE ALERT: Bragar Eagel & Squire, P.C. is Investigating Repare Therapeutics Inc. on Behalf of Rep...
GlobeNewswire
13/02
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Busine...
GlobeNewswire
30/01
COUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha ...
GlobeNewswire
03/01
US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Haltin...
GlobeNewswire
03/01
Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Tria...
GlobeNewswire
29/12/2023
LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
GlobeNewswire
14/12/2023
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibo...